Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2021; 121(03): 332-340
DOI: 10.1055/s-0040-1718373
Cellular Haemostasis and Platelets

The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia

Man-Chiu Poon 
1   Department of Medicine, Pediatrics and Oncology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
2   Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Centre, Calgary, Alberta, Canada
› Author Affiliations Funding This work was supported by Novo Nordisk.
› Further Information
   Permissions and Reprints

Abstract

Platelet transfusion is the standard treatment to control or prevent bleeding in patients with Glanzmann's thrombasthenia (GT), but platelets are often unavailable. Recombinant activated factor VII (rFVIIa) is an effective alternative to platelets in patients with GT with past/present refractoriness to platelet transfusions and antibodies to platelets. However, there is an unmet need for an alternative to platelets in patients without antibodies. This report summarizes evidence of efficacy and safety of rFVIIa in patients with GT without refractoriness or antibodies to platelets from three different sources: the Glanzmann's Thrombasthenia Registry (GTR), published literature (January 01, 1999 to December 01, 2017), and the Novo Nordisk safety surveillance database. In the GTR, 133 patients received rFVIIa for the treatment of 333 bleeding episodes and prevention of bleeding in 157 surgical procedures. Overall efficacy rates were 79 and 88%, respectively, in patients treated for bleeding episodes or for the prevention of bleeding during surgery; effectiveness was generally similar across refractoriness/antibody status categories. Median dose per infusion of rFVIIa was close to that recommended for patients with GT (90 µg/kg). Data from 14 published case reports also demonstrated that rFVIIa is effective with an acceptable safety profile in patients with GT without antibodies to platelets. Analysis of adverse events reported in GTR and in Novo Nordisk safety surveillance database did not raise any new safety concerns. These data supported the label extension of rFVIIa to include cases where platelets are not readily available, which was approved by the European Medicines Agency in December 2018.

Keywords

Glanzmann's thrombasthenia - rFVIIa - integrin α2bβ3 - bleeding

Supplementary Material



Publication History

Received: 04 May 2020

Accepted: 25 August 2020

Article published online:
29 October 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (07) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 2 Nurden AT. Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?. Blood Rev 2017; 31 (05) 287-299
    CrossrefPubMedGoogle Scholar
  • 3 Solh T, Botsford A, Solh M. Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 2015; 6: 219-227
    CrossrefPubMedGoogle Scholar
  • 4 Poon MC, Di Minno G, d'Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev 2016; 30 (02) 92-99
    CrossrefPubMedGoogle Scholar
  • 5 Poon MC, d'Oiron R. Alloimmunization in congenital deficiencies of platelet surface glycoproteins: focus on Glanzmann's thrombasthenia and Bernard-Soulier's Syndrome. Semin Thromb Hemost 2018; 44 (06) 604-614
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17 (05) e858-e869
    CrossrefPubMedGoogle Scholar
  • 7 Bellucci S, Caen J. Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev 2002; 16 (03) 193-202
    CrossrefPubMedGoogle Scholar
  • 8 Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24 (02) 77-124
    CrossrefPubMedGoogle Scholar
  • 9 Carson JL, Guyatt G, Heddle NM. et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 316 (19) 2025-2035
    CrossrefPubMedGoogle Scholar
  • 10 European Medical Agency. NovoSeven EPAR assessment report. Available at: https://www.ema.europa.eu/en/documents/variation-report/novoseven-h-c-000074-ii-0104-epar-assessment-report-variation_en.pdf . Accessed July 2020
    PubMedGoogle Scholar
  • 11 Poon MC, d'Oiron R, Zotz RB, Bindslev N, Di Minno MN, Di Minno G. Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 2015; 100 (08) 1038-1044
    PubMedGoogle Scholar
  • 12 Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC. Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 2015; 100 (08) 1031-1037
    PubMedGoogle Scholar
  • 13 Poon MC, D'Oiron R, Von Depka M. et al. International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2 (07) 1096-1103
    CrossrefPubMedGoogle Scholar
  • 14 Chitlur MEN, Kraut EH, Cooper DL. Recombinant factor VIIa (rFVIIa) use in glanzmann's thrombasthenia (GT) and other platelet disorders (OPDS): hemophilia and thrombosis research society (HTRS) registry data (abstract). J Thromb Haemost 2011; 9 (Suppl 02): 340
    PubMedGoogle Scholar
  • 15 Bomke BHT, Dücker C, Scharf RE. Platelet-free hemotherapy in patients with Bernard Soulier syndrome (BSS) and Glanzmann's thrombasthenia (GT): successful bleeding prophylaxis with recombinant Factor VIIa (rFVIIa) for elective surgery (abstract). Hamostaseologie 2010; 30: A26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Bowles L, Pasi J, Hart D. et al. Ovarian endometrioma in two women with Glanzmann's thrombasthenia (abstract). Haemophilia 2012; 18 (Suppl 03): 203-204
    PubMedGoogle Scholar
  • 17 Ceglarek B, Sikorska A, Bykowska K. et al. Effective therapy with recombinant factor VIIa in female patient suffering from Glanzmann thrombasthenia – the own experience (abstract). Acta Haematol Pol 2015; 46S: 88
    CrossrefPubMedGoogle Scholar
  • 18 Elshinawy M, Al-Rawas A, Wali Y. Coexistence of Glanzmann's thrombasthenia and maple syrup urine disease (MSUD): Implications for hemostatic management (abstract). Haematologica 2017; 102 (Suppl. 02) 839
    PubMedGoogle Scholar
  • 19 Gunes AM, Evim MS, Birol B. The use of recombinant FVIIa in two children with Glanzmann's thrombasthenia with severe bleeding after trauma: po-tu-162 (abstract). Haemophilia 2012; 18 (Suppl 03): 148
    CrossrefPubMedGoogle Scholar
  • 20 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94 (11) 3951-3953
    CrossrefPubMedGoogle Scholar
  • 21 Staritz P, Zimmermann R, Domschke C. et al. Successful IVF and pregnancy in Glanzmann's thrombasthenia under cover of recombinant factor VIIa: Po 355 (abstract). J Thromb Haemost 2013; 11 (Suppl 02): 1153-1154
    PubMedGoogle Scholar
  • 22 Tsakiris DA, Graf L, Brunner S. et al. Successful ankle replacement in a patient with Glanzmann thrombasthenia: a case report: 80 (abstract). Haemophilia 2012; 18 (Suppl 01): 49-50
    CrossrefPubMedGoogle Scholar
  • 23 Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. J Pediatr Hematol Oncol 2006; 28 (10) 653-658
    CrossrefPubMedGoogle Scholar
  • 24 Ward J, Maddox J, Kerr R. Glanzmann thrombasthaenia - a single centre experience of different therapeutic approaches to achieve haemostasis in 3 patients (abstract). Haemophilia 2010; 16 (Suppl 04): 123
    CrossrefPubMedGoogle Scholar
  • 25 Nunez R, Perez-Garrido R. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia (abstract). J Thromb Haemost 2009; 7 (Suppl 02): 888
    PubMedGoogle Scholar
  • 26 van Buuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002; 47 (09) 2134-2136
    CrossrefPubMedGoogle Scholar
  • 27 d'Oiron R, Ménart C, Trzeciak MC. et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83 (05) 644-647
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Poon M-C, Di Minno G, Zotz R. et al. Glanzmann's thrombasthenia: strategies for identification and management. Expert Opin Orphan Drugs 2017; 5 (08) 641-653
    CrossrefPubMedGoogle Scholar
  • 29 European Medical Agency. NovoSeven summary of product characteristics. Accessed September 19, 2020 at: https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf
    PubMedGoogle Scholar
  • 30 Zotz RB, Poon MC, Di Minno G, D'Oiron R. Glanzmann Thrombasthenia Registry Investigators. The international prospective Glanzmann Thrombasthenia Registry: pediatric treatment and outcomes. TH Open 2019; 3 (03) e286-e294
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Neufeld EJ, Négrier C, Benchikh El Fegoun S, Cooper DL, Rojas-Rios A, Seremetis S. Recombinant activated factor VII in approved indications: Update on safety. Haemophilia 2018; 24 (04) e275-e277
    CrossrefPubMedGoogle Scholar